MabVax Therapeutics Secures First Series B Tranche

By Angela Sormani — 3 years ago

MabVax Therapeutics, a privately held clinical stage biotechnology company has closed the first tranche in a Series B financing. Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million.